IL17 functions through the novel REG3β-JAK2-STAT3 inflammatory pathway to promote the transition from chronic pancreatitis to pancreatic cancer

Celine Loncle, Laia Bonjoch, Emma Folch-Puy, Maria Belen Lopez-Millan, Sophie Lac, Maria Inés Molejon, Eduardo Chuluyan, Pierre Cordelier, Pierre Dubus, Gwen Lomberk, Raul Urrutia, Daniel Closa, Juan L. Iovanna

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) offers an optimal model for discovering "druggable" molecular pathways that participate in inflammation-associated cancer development. Chronic pancreatitis, a common prolonged inflammatory disease, behaves as a well-known premalignant condition that contributes to PDAC development. Although the mechanisms underlying the pancreatitis-to-cancer transition remain to be fully elucidated, emerging evidence supports the hypothesis that the actions of proinflammatory mediators on cells harboring Kras mutations promote neoplastic transformation. Recent elegant studies demonstrated that the IL17 pathway mediates this phenomenon and can be targeted with antibodies, but the downstream mechanisms by which IL17 functions during this transition are currently unclear. In this study, we demonstrate that IL17 induces the expression of REG3β, a wellknown mediator of pancreatitis, during acinar-to-ductal metaplasia and in early pancreatic intraepithelial neoplasia (PanIN) lesions. Furthermore, we found that REG3β promotes cell growth and decreases sensitivity to cell death through activation of the gp130-JAK2-STAT3-dependent pathway. Genetic inactivation of REG3β in the context of oncogenic Kras-driven PDAC resulted in reduced PanIN formation, an effect that could be rescued by administration of exogenous REG3β. Taken together, our findings provide mechanistic insight into the pathways underlying inflammation-associated pancreatic cancer, revealing a dual and contextual pathophysiologic role for REG3β during pancreatitis and PDAC initiation.

Original languageEnglish (US)
Pages (from-to)4852-4862
Number of pages11
JournalCancer Research
Volume75
Issue number22
DOIs
StatePublished - Nov 15 2015

Fingerprint

Chronic Pancreatitis
Pancreatic Neoplasms
Adenocarcinoma
Pancreatitis
Neoplasms
Inflammation
Metaplasia
Cell Death
Mutation
Antibodies
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Loncle, C., Bonjoch, L., Folch-Puy, E., Lopez-Millan, M. B., Lac, S., Molejon, M. I., ... Iovanna, J. L. (2015). IL17 functions through the novel REG3β-JAK2-STAT3 inflammatory pathway to promote the transition from chronic pancreatitis to pancreatic cancer. Cancer Research, 75(22), 4852-4862. https://doi.org/10.1158/0008-5472.CAN-15-0896

IL17 functions through the novel REG3β-JAK2-STAT3 inflammatory pathway to promote the transition from chronic pancreatitis to pancreatic cancer. / Loncle, Celine; Bonjoch, Laia; Folch-Puy, Emma; Lopez-Millan, Maria Belen; Lac, Sophie; Molejon, Maria Inés; Chuluyan, Eduardo; Cordelier, Pierre; Dubus, Pierre; Lomberk, Gwen; Urrutia, Raul; Closa, Daniel; Iovanna, Juan L.

In: Cancer Research, Vol. 75, No. 22, 15.11.2015, p. 4852-4862.

Research output: Contribution to journalArticle

Loncle, C, Bonjoch, L, Folch-Puy, E, Lopez-Millan, MB, Lac, S, Molejon, MI, Chuluyan, E, Cordelier, P, Dubus, P, Lomberk, G, Urrutia, R, Closa, D & Iovanna, JL 2015, 'IL17 functions through the novel REG3β-JAK2-STAT3 inflammatory pathway to promote the transition from chronic pancreatitis to pancreatic cancer', Cancer Research, vol. 75, no. 22, pp. 4852-4862. https://doi.org/10.1158/0008-5472.CAN-15-0896
Loncle, Celine ; Bonjoch, Laia ; Folch-Puy, Emma ; Lopez-Millan, Maria Belen ; Lac, Sophie ; Molejon, Maria Inés ; Chuluyan, Eduardo ; Cordelier, Pierre ; Dubus, Pierre ; Lomberk, Gwen ; Urrutia, Raul ; Closa, Daniel ; Iovanna, Juan L. / IL17 functions through the novel REG3β-JAK2-STAT3 inflammatory pathway to promote the transition from chronic pancreatitis to pancreatic cancer. In: Cancer Research. 2015 ; Vol. 75, No. 22. pp. 4852-4862.
@article{6a6bdf8852c448c3866bc81d99d007b8,
title = "IL17 functions through the novel REG3β-JAK2-STAT3 inflammatory pathway to promote the transition from chronic pancreatitis to pancreatic cancer",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) offers an optimal model for discovering {"}druggable{"} molecular pathways that participate in inflammation-associated cancer development. Chronic pancreatitis, a common prolonged inflammatory disease, behaves as a well-known premalignant condition that contributes to PDAC development. Although the mechanisms underlying the pancreatitis-to-cancer transition remain to be fully elucidated, emerging evidence supports the hypothesis that the actions of proinflammatory mediators on cells harboring Kras mutations promote neoplastic transformation. Recent elegant studies demonstrated that the IL17 pathway mediates this phenomenon and can be targeted with antibodies, but the downstream mechanisms by which IL17 functions during this transition are currently unclear. In this study, we demonstrate that IL17 induces the expression of REG3β, a wellknown mediator of pancreatitis, during acinar-to-ductal metaplasia and in early pancreatic intraepithelial neoplasia (PanIN) lesions. Furthermore, we found that REG3β promotes cell growth and decreases sensitivity to cell death through activation of the gp130-JAK2-STAT3-dependent pathway. Genetic inactivation of REG3β in the context of oncogenic Kras-driven PDAC resulted in reduced PanIN formation, an effect that could be rescued by administration of exogenous REG3β. Taken together, our findings provide mechanistic insight into the pathways underlying inflammation-associated pancreatic cancer, revealing a dual and contextual pathophysiologic role for REG3β during pancreatitis and PDAC initiation.",
author = "Celine Loncle and Laia Bonjoch and Emma Folch-Puy and Lopez-Millan, {Maria Belen} and Sophie Lac and Molejon, {Maria In{\'e}s} and Eduardo Chuluyan and Pierre Cordelier and Pierre Dubus and Gwen Lomberk and Raul Urrutia and Daniel Closa and Iovanna, {Juan L.}",
year = "2015",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-15-0896",
language = "English (US)",
volume = "75",
pages = "4852--4862",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - IL17 functions through the novel REG3β-JAK2-STAT3 inflammatory pathway to promote the transition from chronic pancreatitis to pancreatic cancer

AU - Loncle, Celine

AU - Bonjoch, Laia

AU - Folch-Puy, Emma

AU - Lopez-Millan, Maria Belen

AU - Lac, Sophie

AU - Molejon, Maria Inés

AU - Chuluyan, Eduardo

AU - Cordelier, Pierre

AU - Dubus, Pierre

AU - Lomberk, Gwen

AU - Urrutia, Raul

AU - Closa, Daniel

AU - Iovanna, Juan L.

PY - 2015/11/15

Y1 - 2015/11/15

N2 - Pancreatic ductal adenocarcinoma (PDAC) offers an optimal model for discovering "druggable" molecular pathways that participate in inflammation-associated cancer development. Chronic pancreatitis, a common prolonged inflammatory disease, behaves as a well-known premalignant condition that contributes to PDAC development. Although the mechanisms underlying the pancreatitis-to-cancer transition remain to be fully elucidated, emerging evidence supports the hypothesis that the actions of proinflammatory mediators on cells harboring Kras mutations promote neoplastic transformation. Recent elegant studies demonstrated that the IL17 pathway mediates this phenomenon and can be targeted with antibodies, but the downstream mechanisms by which IL17 functions during this transition are currently unclear. In this study, we demonstrate that IL17 induces the expression of REG3β, a wellknown mediator of pancreatitis, during acinar-to-ductal metaplasia and in early pancreatic intraepithelial neoplasia (PanIN) lesions. Furthermore, we found that REG3β promotes cell growth and decreases sensitivity to cell death through activation of the gp130-JAK2-STAT3-dependent pathway. Genetic inactivation of REG3β in the context of oncogenic Kras-driven PDAC resulted in reduced PanIN formation, an effect that could be rescued by administration of exogenous REG3β. Taken together, our findings provide mechanistic insight into the pathways underlying inflammation-associated pancreatic cancer, revealing a dual and contextual pathophysiologic role for REG3β during pancreatitis and PDAC initiation.

AB - Pancreatic ductal adenocarcinoma (PDAC) offers an optimal model for discovering "druggable" molecular pathways that participate in inflammation-associated cancer development. Chronic pancreatitis, a common prolonged inflammatory disease, behaves as a well-known premalignant condition that contributes to PDAC development. Although the mechanisms underlying the pancreatitis-to-cancer transition remain to be fully elucidated, emerging evidence supports the hypothesis that the actions of proinflammatory mediators on cells harboring Kras mutations promote neoplastic transformation. Recent elegant studies demonstrated that the IL17 pathway mediates this phenomenon and can be targeted with antibodies, but the downstream mechanisms by which IL17 functions during this transition are currently unclear. In this study, we demonstrate that IL17 induces the expression of REG3β, a wellknown mediator of pancreatitis, during acinar-to-ductal metaplasia and in early pancreatic intraepithelial neoplasia (PanIN) lesions. Furthermore, we found that REG3β promotes cell growth and decreases sensitivity to cell death through activation of the gp130-JAK2-STAT3-dependent pathway. Genetic inactivation of REG3β in the context of oncogenic Kras-driven PDAC resulted in reduced PanIN formation, an effect that could be rescued by administration of exogenous REG3β. Taken together, our findings provide mechanistic insight into the pathways underlying inflammation-associated pancreatic cancer, revealing a dual and contextual pathophysiologic role for REG3β during pancreatitis and PDAC initiation.

UR - http://www.scopus.com/inward/record.url?scp=84955115797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955115797&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-0896

DO - 10.1158/0008-5472.CAN-15-0896

M3 - Article

C2 - 26404002

AN - SCOPUS:84955115797

VL - 75

SP - 4852

EP - 4862

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 22

ER -